LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
=== Blood symptoms === The characteristic hematological (blood) effects of copper deficiency are anemia (which may be microcytic, normocytic or macrocytic) and neutropenia. Thrombocytopenia (low blood platelets) is unusual. The peripheral blood and bone marrow aspirate findings in copper deficiency can mimic myelodysplastic syndrome. Bone marrow aspirate in both conditions may show dysplasia of blood cell precursors and the presence of ring sideroblasts (erythroblasts containing multiple iron granules around the nucleus). Unlike most cases of myelodysplastic syndrome, the bone marrow aspirate in copper deficiency characteristically shows cytoplasmic vacuoles within red and white cell precursors, and karyotyping in cases of copper deficiency does not reveal cytogenetic features characteristic of myelodysplastic syndrome. Anemia and neutropenia typically resolve within six weeks of copper replacement.
=== International growth === By 1987, the company was operating across the Northern United States, purchasing the Mother's Pizza chain out of receivership in Canada, the United States, and the United Kingdom in 1989 (left between 2000 and 2022). As of 2022, the company is present in Canada (some Canadian cities had locations since 1969), Honduras, Nicaragua, Saudi Arabia, Costa Rica, Dominican Republic, Mexico (since 2006), Colombia, Panama, Peru, Turkey, Guatemala, Barbados, Bahamas, El Salvador, Jamaica, Bahrain, Trinidad and Tobago, Chile, Spain, and Singapore. The Little Caesars brand began operating in the Philippines in the 1990s, but it gradually closed down in the 2000s. It re-entered the market on January 25, 2019, launching under a new franchisee and new branch in Ermita, Manila. In 2019, Little Caesars restaurants in Australia closed their doors and went into administration, having entered the Australian market in 2014. Little Caesars entered the Indian market on January 29, 2020, opening two stores in Ahmedabad, Gujarat. In March 2022, Little Caesars left Russia due to the War in Ukraine. In December 2022, the company re-entered the UK market after 22 years, opening a store in Derby, followed by stores in Greenford and Nottingham in 2024.By 2026 however they would quietly and slowly close down all of their locations, with the Greenford branch being the last location to shut its doors, exiting the UK market once more after 4 years.
== SY == SY – (s) Syria (ISO 3166 and FIPS 10-4 country code digram) SYC – (s) Seychelles (ISO 3166 trigram) SYLK – Microsoft 'Symbolic Link' data file format SYP – (s) Syrian pound (ISO 4217 currency code) SYR – (s) Syria (ISO 3166 trigram) Syriza – (p) Synaspismós Rizospastikís Aristerás (Greek Συνασπισμός Ριζοσπαστικής Αριστεράς, "Coalition of the Radical Left") SysML – (p) System Modeling Language Sysop – (p) System Operator
Sources: en.wikipedia.org
== Adverse effects == Common adverse drug reactions (≥1% of patients) associated with ezetimibe therapy include headache and/or diarrhea (steatorrhea). Infrequent adverse effects (0.1–1% of patients) include myalgia and/or raised liver function test (ALT/AST) results. Rarely (<0.1% of patients), hypersensitivity reactions (rash, angioedema) or myopathy may occur. Cases of muscle problems (myalgia and rhabdomyolysis) have been reported and are included as warnings on the label for ezetimibe. Since NPC1L1 also regulates vitamin K uptake, the use of ezetimibe can lead to side effects in warfarin therapy.
== Classification == Chronic kidney disease in cats is currently divided into four main stages by the International Renal Interest Society (IRIS) and adapted by the European Society of Veterinary Nephrology and Urology, with the creatinine concentration in blood plasma being used as the main criterion. In addition, sub-stages are defined on the basis of the protein-creatinine quotient in the urine and blood pressure. The plasma creatinine concentration should be ensured by at least two measurements at intervals of one to two weeks, the protein-creatinine quotient in the urine by two or three measurements over a period of two to four weeks. As creatinine is also influenced by other factors, since 2019 the Symmetric dimethylarginine (SDMA) is also used for assessment. In diabetic cats SDMA may be reduced.
Post-translational modifications (PTMs) are the covalent processes of changing proteins following their synthesis, and release from ribosomes. PTMs are reversible editing events used and carried out in the overall process of post-translational regulation – the control of the levels of active protein; an irreversible event is proteolysis (protein degradation). PTMs enable the protein's function to be diversified and extended beyond the dictates of transcription. As of 2023 there are more than 650 known types of PTM. PTMs are also prokaryotic processes. PTMs may involve enzymes or occur spontaneously. Proteins are created by ribosomes, which translate mRNA into polypeptide chains, which may then change to form the mature protein product, which is then released from the ribosome. PTMs are important components in cell signalling, as for example when prohormones are converted to hormones. Post-translational modifications can occur on the amino acid side chains or at the protein's C- or N- termini. They can expand the chemical set of the 22 amino acids by changing an existing functional group or adding a new one such as phosphate. Phosphorylation is highly effective for controlling the enzyme activity and is the most common change after translation. Many eukaryotic and prokaryotic proteins also have carbohydrate molecules attached to them in a process called glycosylation, which can promote protein folding and improve stability as well as serving regulatory functions.
In 1887 Johannes Wislicenus published a study of stereoisomerism in unsaturated compounds. Groth made a systematic classification of minerals based on their chemical composition and crystal structure and published his results in his 5-volume Chemische Kristallographie in 1906–1919, which contained crystalline morphology and physical property data on nearly 10,000 substances. In 1913 Walter Wahl summarised the known connections between chemical composition and crystalline form as isomorphism (Mitscherlich), morphotropism (Groth), and enantiomorphism (Pasteur and van 't Hoff). In his preface to Andreas Fock's An introduction to chemical crystallography Pope summarised the state of chemical crystallography in 1895 as follows:
Sources: en.wikipedia.org
Egypt (c. 1600–1500 BCE): The Edwin Smith Papyrus (c. 1600 BCE), one of the earliest known surgical texts, describes wound treatments involving cleansing, bandaging, and poultice-like applications made with honey and animal fats. The Ebers Papyrus (c. 1550 BCE) contains numerous recipes for poultices combining lint, honey, and grease, applied to wounds and inflammations. Mesopotamia (c. 2200 BCE): Sumerian clay tablets describe wound washing, herbal dressings, and poultices using ingredients such as milk and beer. India (c. 200 CE): The Sushruta Samhita, a foundational Sanskrit medical encyclopedia, prescribed poultices made of herbs, ghee, and oils for in many contexts including for cleansing wounds and promoting healing. Greece and Rome (c. 400 BCE - 200 CE): Hippocrates (c. 460–370 BCE) recommended cleansing wounds with wine or vinegar, then applying poultices of honey, oil, and wine. In both Greece and Rome, poultices of wool, linen, and crushed plants were commonly used for inflammations and injuries. Later practices During the Middle Ages and Renaissance, poultices made from flour, linseed, mustard, bran, herbs, or bread were widely used in Europe. They were often applied hot to "draw out" infection, relieve swelling, or soften abscesses. Poultices subsequently remained a standard remedy in both civilian and military medicine.
The band had been using drum tapes on tour before Thomas. Their next release was the new recording "Sidewalking", released in March 1988, and backed by some of the live tracks, followed a month later by Barbed Wire Kisses. Later that year, they did a remix for the single "Birthday" by The Sugarcubes. In September 1989, The band provided backing vocals for the Erasure single "Drama!". The band's third studio album, Automatic, was released in October 1989, by which time Evans had been replaced by Ben Lurie. Boasting heavy use of synthesized bass and keyboards, the album was not received quite as well as its predecessors. It contained the singles "Head On" and "Blues from a Gun". By this time, the violence that was originally associated with the band was practically non-existent and the Reid brothers were less antagonistic and aggressive in general. The Rollercoaster EP (August 1990) would be their last release for over a year, the band undertaking a tour of the same name with My Bloody Valentine, Dinosaur Jr., and Blur.
Dr. Reddy's originally launched in 1984 producing active pharmaceutical ingredients. In 1986, Reddy's started operations on branded formulations. Within a year Reddy's had launched Norilet, the company's first recognised brand in India. Soon, Dr. Reddy's obtained another success with Omez, its branded omeprazole – gastrointestinal ulcer and reflux oesophagitis medication – launched at half the price of other brands on the Indian market at that time. Within a year, Reddy's became the first Indian company to export the active ingredients for pharmaceuticals to Europe. In 1987, Reddy's started to transform itself from a supplier of pharmaceutical ingredients to other manufacturers into a manufacturer of pharmaceutical products. In 1999, Dr. Reddy's joined the Indian Pharmaceutical Alliance as a founding member in an effort to promote the development of generic drugs in India.
Waterproofing the skin while in gestation Lubricating the infant's skin and facilitating easy passage through the birth canal Preventing infections — primarily as a mechanical barrier and secondarily via the presence of lysozyme, lactoferrin, and antimicrobial components in the peptide layer Moisturizing the stratum corneum while in gestation (and controlling drying in the postpartum period) Thermoregulation in the postpartum phase (Evidence is mixed.) Quick healing of epidermal wounds Development of the gut after intra-uterine consumption Vernix caseosa is thought to cause electrical isolation of the fetus, which could affect accurate fECG measurement of the fetal heartbeat.
== Privacy concerns with direct TPMS == Because each tire transmits a unique identifier, vehicles may be easily tracked using existing sensors along the roadway. This concern could be addressed by encrypting the radio communications from the sensors but such privacy provisions were not stipulated by the NHTSA.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.